Skip to main content
Top
Published in: Rheumatology International 10/2013

01-10-2013 | Original Article

Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study

Authors: Omer Nuri Pamuk, Bunyamin Kisacik, Gulsum Emel Pamuk, Ahmet Mesut Onat, Mehmet Sayarlioglu, Salim Donmez, Yavuz Pehlivan, Edward C. Keystone

Published in: Rheumatology International | Issue 10/2013

Login to get access

Abstract

We evaluated the roles of sociocultural status, distress and cognitive functions in rheumatoid arthritis (RA) patients who developed methotrexate (MTX)-related neutropenia. The data of 37 RA patients with MTX-related neutropenia who were being followed up at 3 centers were evaluated. The control group included 74 RA patients. The clinical features, biochemical tests and treatment modalities of the patients were obtained from hospital files. The mini-mental state examination (MMSE) test and the Hospital Anxiety and Depression Scale (HADS) were administered for all RA patients with neutropenia as well as the control group. The frequencies of male patients, illiterate patients, patients living alone, patients with serious visual impairment, those with low income, and patients with high creatinine were significantly higher among RA patients with MTX-related neutropenia than in controls (p values <0.05). The RA patients with MTX-related neutropenia had significantly lower MMSE scores, and significantly higher HADS-A and HADS-D scores than controls (p values <0.05). In addition, the proportion of patients with probable dementia was significantly higher in RA patients with MTX-related neutropenia than in controls (p < 0.001). Twenty-six of the 37 patients (70.3 %) developed neutropenia with daily dosing. Patients who used MTX daily were more likely to be living alone than those using weekly dosing (p = 0.011). Multivariate analysis showed that having probable dementia on the MMSE test (OR 52.6), low income level (OR 56.8) and age (OR 1.12) were independent risk factors for the development of MTX-related neutropenia. The presence of probable dementia on MMSE, low socioeconomical status and older age are associated with serious toxicity in RA patients using MTX. Measures should be taken to prevent wrong MTX dosing by the patients. Compliance and patient education is of major importance, in particular, in the patients presented in this study.
Literature
1.
go back to reference Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 18:1323–1327PubMed Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 18:1323–1327PubMed
2.
go back to reference Kremer JM, Phelps CT (1992) Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 35:138–145PubMedCrossRef Kremer JM, Phelps CT (1992) Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 35:138–145PubMedCrossRef
3.
go back to reference Alarcón GS, Tracy IC, Strand GM, Singh K, Macaluso M (1995) Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 54:708–712PubMedCrossRef Alarcón GS, Tracy IC, Strand GM, Singh K, Macaluso M (1995) Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 54:708–712PubMedCrossRef
4.
go back to reference Yazici Y (2010) Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28:S65–S67PubMed Yazici Y (2010) Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28:S65–S67PubMed
5.
go back to reference Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104PubMedCrossRef Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104PubMedCrossRef
6.
go back to reference Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P (2000) Methotrexate for rheumatoid arthritis. Review. Cochrane Database Syst Rev 2:CD000957PubMed Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P (2000) Methotrexate for rheumatoid arthritis. Review. Cochrane Database Syst Rev 2:CD000957PubMed
7.
go back to reference Alarcón GS, Tracy IC, Blackburn WD Jr (1989) Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32(6):671–676PubMedCrossRef Alarcón GS, Tracy IC, Blackburn WD Jr (1989) Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32(6):671–676PubMedCrossRef
8.
go back to reference Verstappen SM, Bakker MF, Heurkens AH et al (2010) Utrecht rheumatoid arthritis cohort study group. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 69:1044–1048PubMedCrossRef Verstappen SM, Bakker MF, Heurkens AH et al (2010) Utrecht rheumatoid arthritis cohort study group. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 69:1044–1048PubMedCrossRef
9.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
10.
go back to reference Folstein MF, Folstein S, Mc Hugh PR (1975) ‘Mini Mental State’ a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198CrossRef Folstein MF, Folstein S, Mc Hugh PR (1975) ‘Mini Mental State’ a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198CrossRef
11.
go back to reference Molloy DW, Alemayehu E, Roberts R (1991) Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 148:102–105PubMed Molloy DW, Alemayehu E, Roberts R (1991) Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 148:102–105PubMed
12.
go back to reference Güngen C, Ertan T, Eker E, Yaşar R, Engin F (2002) Reliability and validity of the standardized mini mental state examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 13:273–281 (Article in Turkish)PubMed Güngen C, Ertan T, Eker E, Yaşar R, Engin F (2002) Reliability and validity of the standardized mini mental state examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 13:273–281 (Article in Turkish)PubMed
13.
go back to reference Friedman TW, Yelland GW, Robinson SR (2011) Subtle cognitive impairment in elders with mini-mental state examination scores within the ‘normal’ range. Int J Geriatr Psychiatry 27:463–471PubMedCrossRef Friedman TW, Yelland GW, Robinson SR (2011) Subtle cognitive impairment in elders with mini-mental state examination scores within the ‘normal’ range. Int J Geriatr Psychiatry 27:463–471PubMedCrossRef
14.
go back to reference Aydemir O (1997) Hastane anksiyete ve depresyon ölçeği Türkçe formunun geçerlilik ve güvenilirlik çalışması. Türk Psikiyatri Dergisi 8:280–287 (Article in Turkish) Aydemir O (1997) Hastane anksiyete ve depresyon ölçeği Türkçe formunun geçerlilik ve güvenilirlik çalışması. Türk Psikiyatri Dergisi 8:280–287 (Article in Turkish)
15.
go back to reference Al-Hasani H, Roussou E (2011) Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 31:1545–1547PubMedCrossRef Al-Hasani H, Roussou E (2011) Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 31:1545–1547PubMedCrossRef
16.
go back to reference Isik A, Koca SS, Ozturk A, Mermi O (2007) Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 26:872–878PubMedCrossRef Isik A, Koca SS, Ozturk A, Mermi O (2007) Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 26:872–878PubMedCrossRef
17.
go back to reference VanDyke MM, Parker JC, Smarr KL et al (2004) Anxiety in rheumatoid arthritis. Arthritis Rheum 51:408–412PubMedCrossRef VanDyke MM, Parker JC, Smarr KL et al (2004) Anxiety in rheumatoid arthritis. Arthritis Rheum 51:408–412PubMedCrossRef
18.
go back to reference Fisher MC, Cronstein BN (2009) Metaanalysis of methylene tetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539–545PubMedCrossRef Fisher MC, Cronstein BN (2009) Metaanalysis of methylene tetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539–545PubMedCrossRef
19.
go back to reference Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572–579PubMed Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572–579PubMed
20.
go back to reference Efrati E, Elkin H, Nahum S, Krivoy N (2013) Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel. Rheumatol Int 33:1001–1004PubMedCrossRef Efrati E, Elkin H, Nahum S, Krivoy N (2013) Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel. Rheumatol Int 33:1001–1004PubMedCrossRef
21.
go back to reference Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG (2008) Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 35:979–985PubMed Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG (2008) Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 35:979–985PubMed
Metadata
Title
Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study
Authors
Omer Nuri Pamuk
Bunyamin Kisacik
Gulsum Emel Pamuk
Ahmet Mesut Onat
Mehmet Sayarlioglu
Salim Donmez
Yavuz Pehlivan
Edward C. Keystone
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2792-2

Other articles of this Issue 10/2013

Rheumatology International 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.